Summary
This study is looking at how safe the drug RO7851624 is, how the body processes it, and how well it works in people with relapsed or refractory multiple myeloma (RRMM).
It is for people who have already been treated with the main types of myeloma medicines (including proteasome inhibitors, immunomodulators, and anti-CD38 antibody treatments), and whose disease has come back or stopped responding. These participants may also have limited standard treatment options remaining due to side effects, lack of response, or having received many prior treatments.